European Commission clears J&J's ustekinumab

01/22/2009 | Bloomberg

Johnson & Johnson announced that the European Commission approved the use of ustekinumab, a psoriasis treatment, for patients who do not benefit from other anti-inflammatory medicines. In December, the FDA deferred its decision on the drug and asked J&J to submit additional safety data.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD